|
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
RECRUITINGPhase 3Sponsored by AstraZeneca
Actively Recruiting
PhasePhase 3
SponsorAstraZeneca
Started2026-08-20
Est. completion2028-08-09
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations56 sites
View on ClinicalTrials.gov →
NCT07784270
Summary
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥27 kg/m2 * Diagnosed with T2DM ≥90 days prior to Screening * HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling) * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 X ULN * AST ≥ 3.0 X ULN * TBL \> 1.5 X ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation * Use of insulin therapy for T2DM within 3 months prior to screening
Conditions3
DiabetesDiabetes Mellitus, Type 2Obesity or Overweight
Interventions1
Locations56 sites
Find trials near these locations
Diabetes trials in MesaDiabetes trials in PhoenixDiabetes trials in TucsonDiabetes trials in ChicagoDiabetes trials in Kansas CityDiabetes trials in OmahaDiabetes trials in El PasoDiabetes trials in HoustonDiabetes trials in San AntonioAll trials in AlabamaAll trials in ArizonaAll trials in ArkansasAll trials in CaliforniaAll trials in FloridaAll trials in GeorgiaAll trials in IllinoisAll trials in IowaAll trials in KansasAll trials in LouisianaAll trials in MarylandAll trials in MassachusettsAll trials in MichiganAll trials in MississippiAll trials in MissouriAll trials in NebraskaAll trials in New JerseyAll trials in North CarolinaAll trials in OhioAll trials in PennsylvaniaAll trials in TennesseeAll trials in TexasAll trials in Virginia
Related trials
- A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus — AstraZeneca
- A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus — AstraZeneca
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorAstraZeneca
Started2026-08-20
Est. completion2028-08-09
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations56 sites
View on ClinicalTrials.gov →
NCT07784270